CN1273485C - Immunoglobulin sample receptor originated from human dendritic cell, its coding sequence and application - Google Patents
Immunoglobulin sample receptor originated from human dendritic cell, its coding sequence and application Download PDFInfo
- Publication number
- CN1273485C CN1273485C CN02136553.9A CN02136553A CN1273485C CN 1273485 C CN1273485 C CN 1273485C CN 02136553 A CN02136553 A CN 02136553A CN 1273485 C CN1273485 C CN 1273485C
- Authority
- CN
- China
- Prior art keywords
- hudigr
- polypeptide
- polynucleotide
- people
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Abstract
The present invention relates to a novel human dendritic cell derived immunoglobulin like receptor (HuDIgR). The present invention provides polynucleotide for coding molecules of the protein and a method for producing the protein by recombination technology. The present invention also discloses the applications of an HuDIgR polypeptide and the polynucleotide coding sequence of the polypeptide. The present invention also proves that HuDIg can collect the characteristics of tyrosine phosphatase SHP-1 SHP-2 and SHIP by phosphorylated tyrosine. The present invention also discloses the diagnosis and therapeutic strategies of diseases by molecules resisting the protein. The present invention can be particularly used for diagnosing and treating cancers.
Description
Technical field
The invention belongs to biotechnology and medical field, specifically, the present invention relates to the polynucleotide of the immunoglobulin-like receptor HuDIgR polypeptide of the new novel originated from human dendritic cell of coding people, and the polypeptide of this polynucleotide encoding.The invention still further relates to the purposes and the preparation of these polynucleotide and polypeptide.HuDIgR be a kind of new and the identification of cell surface sugar chain, in conjunction with and the relevant cell surface protein of signal conduction, HuDIg can raise tyrosine phosphatase SHP-1 by the tyrosine of its phosphorylation, SHP-2 and SHIP.
Background technology
The immunoglobulin-like receptor of finding in hematopoiesis and immunocyte (inhibitory immunoreceptor) is a hot subject of field of immunology in recent years.The constructional feature of immunoglobulin-like receptor be contain the relevant inhibitory motifs of one or more immunity receptor tyrosine (immunoreceptor tyrosine-basedinhibitory motifs, ITIM).The conserved sequence that ITIM is made up of 6 amino acid (S/I/L/VxYxxL/V), when immunoglobulin-like receptor and costimulatory receptor coupling, tyrosine phosphorylation takes place in ITIM, can contain the phosphoesterase of SH-2 structural domain in conjunction with cell, as SHP-1, SHP-2, and/or SHIP, this makes phosphoesterase have catalytic activity in conjunction with meeting, produces the negative adjusting effect of cell activation.
Along with to the going deep into of the structure of immunoglobulin-like receptor and biological function research, it is found that immunoglobulin-like receptor all brings into play critical function in the various biological incident.In the intracellular region of most of immunoglobulin-like receptors, all have possible tyrosine phosphorylation site, be positioned at immunity receptor inhibitory motifs based on tyrosine (immunoreceptor tyrosine-based inhibitory motif, ITIM) in.These tyrosine by phosphorylation after, can by raise with active cells in Phosphoric acid esterase (SHP-1, SHP-2 or SHIP) mediate negative conditioning signal.Can be as siglec-3/CD33 and siglec-7/AIRM1 at the negative conditioning signal of specific antibody crosslinked back conduction; The gene knockout experiment of siglec-2/CD22 also is confirmed that it is the down regulator of B cell activation.
In view of the critical function of immunoglobulin-like receptor, this area presses for the new immunoglobulin-like receptor of exploitation.
Summary of the invention
The immunoglobulin-like receptor HuDIgR albumen that the purpose of this invention is to provide a kind of novel originated from human dendritic cell with and fragment, analogue and derivative.
Another object of the present invention provides the polynucleotide of these polypeptide of coding.
Another object of the present invention provides the method for these polypeptide of production and the purposes of this polypeptide and encoding sequence.
In a first aspect of the present invention, novel isolated HuDIgR polypeptide is provided, this polypeptide is the people source, it comprises: polypeptide or its conservative property variation polypeptide or its active fragments or its reactive derivative with SEQ ID NO:2 aminoacid sequence.Preferably, this polypeptide is selected from down group: the polypeptide that (a) has SEQ ID NO:2 aminoacid sequence; (b) SEQ ID NO:2 aminoacid sequence is formed through replacement, disappearance or the interpolation of one or more amino-acid residues, and have raise tyrosine phosphatase SHP-1, SHP-2 or SHIP function by (a) polypeptides derived.
In a second aspect of the present invention, the polynucleotide of isolating these polypeptide of coding are provided, these polynucleotide comprise a nucleotide sequence, and this nucleotide sequence is shown at least 70% homogeny with a kind of nucleotides sequence that is selected from down group: (a) polynucleotide of the above-mentioned people HuDIgR of coding; (b) with polynucleotide (a) complementary polynucleotide.Preferably, this polynucleotide encoding has the polypeptide of aminoacid sequence shown in the SEQ ID NO:2.More preferably, the sequence of these polynucleotide is be selected from down group a kind of: the sequence that (a) has 7-876 position among the SEQ ID NO:1; (b) has the sequence of 1-1696 position among the SEQ ID NO:1.
In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.
In a fourth aspect of the present invention, provide preparation to have the method for the polypeptide of people HuDIgR protein-active, this method comprises: (a) under the proteic condition of suitable expressing human HuDIgR, cultivate the above-mentioned host cell that is transformed or transduce; (b) from culture, isolate polypeptide with people HuDIgR protein-active.
In a fifth aspect of the present invention, provide and above-mentioned people HuDIgR polypeptid specificity bonded antibody.The nucleic acid molecule that can be used for detecting also is provided, and it contains a successive 10-1696 Nucleotide in the above-mentioned polynucleotide.
In a sixth aspect of the present invention, the compound of simulation, promotion, antagonism people HuDIgR polypeptide active is provided, and the compound that suppresses people HuDIgR polypeptide expression.The method of screening and/or prepare these compounds also is provided.Preferably, this compound is encoding sequence or its segmental antisense sequences of people HuDIgR polypeptide.
In a seventh aspect of the present invention, provide and whether had the proteic method of HuDIgR in the test sample, it comprises: sample is contacted with the proteic specific antibody of HuDIgR, observe whether form antibody complex, formed antibody complex and just represented to exist in the sample HuDIgR albumen.
In a eighth aspect of the present invention, a kind of disease relevant with people HuDIgR polypeptide unconventionality expression or method of disease susceptibility of detecting is provided, this method comprises: whether have sudden change in the nucleotide sequence of detection coding said polypeptide.
In a ninth aspect of the present invention, provide the purposes of polypeptide of the present invention and encoding sequence.Polypeptide for example of the present invention can be used to screen the agonist that promotes people HuDIgR polypeptide active, and perhaps screening suppresses the antagonist of people HuDIgR polypeptide active or is used to the peptide finger print identification.The proteic encoding sequence of people HuDIgR of the present invention or its fragment can be used as primer and be used for pcr amplification reaction, perhaps are used for hybridization as probe, perhaps are used to make gene chip or microarray.
In a tenth aspect of the present invention, a kind of pharmaceutical composition is provided, it contains people HuDIgR polypeptide of the present invention or its agonist, antagonist and the pharmaceutically acceptable carrier of safe and effective amount.These pharmaceutical compositions can be treated illnesss such as tumour, inflammation, neural system and cardiovascular diseases.
Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.
Description of drawings
Fig. 1 is people HuDIgR albumen of the present invention and the proteic amino acid sequence homology comparison diagram of immunoglobulin-like receptor family member.The top sequence is people HuDIgR, and the below sequence is an immunoglobulin-like receptor family member albumen.Identical amino acid marks with black matrix between a plurality of sequences, and similar amino acid marks with grey body.Amino-acid residue shown in the circle is that sialic acid is in conjunction with necessary residue; Arrow marks the boundary in different structure territory; ITIM motif for inferring in the square frame.
Fig. 2 is the hydrophobicity graphic representation of the proteic Kyte-doolitte hydrophobicity analysis of people HuDIgR of the present invention.
Fig. 3 is a people HuDIgR RT-PCR expression analysis of the present invention, and prompting HuDIgR is expressed in the monocyte in some tumour cell and human peripheral source; In the reactivation process that the dendritic cell that the human peripheral blood mononuclear cell originates is stimulated by LPS, has the certain expression pattern.
Fig. 4 is the shown distribution of people HuDIgR Northern blot hybridization of the present invention.Results suggest HuDIgR is the molecule that a kind of tool particular organization distributes.
Fig. 5 is that people HuDIgR of the present invention can raise tyrosine phosphatase SHP-1 by the tyrosine of its phosphorylation, SHP-2 and SHIP.First swimming lane: Cos 7 cells of the HuDIgR transfection of handling with inhibitors of phosphatases not; Second swimming lane: Cos 7 cells of the HuDIgR transfection of handling with inhibitors of phosphatases.
Embodiment
Through extensive random sequencing and homology relatively, the inventor separates from human dendritic cell (DC) cDNA library and obtains a new EST, total length 1696bp, the 290 amino acid whose albumen of encoding.Utilize ANTHEPROT and ExPASy software analysis to show, the N-end is the extracellular fragment that 156 amino acid constitute, contain an immunoglobulin (Ig) V district, comprise 23 amino acid whose signal peptides, 156-178AA is that a hydrophobicity is striden the film district, the C-end is 112 amino acid whose born of the same parents' inner segments, and pointing out this molecule is an I type transmembrane protein; Contain LCYADL and ISYASL structure in the intracellular region section, meet the relevant inhibitory motifs ITIM of tyrosine in this immunity receptor of S/I/L/VxYxxL/V.Constitutional features according to this a part, think that it is an immunoglobulin-like receptor new in the immunoglobulin superfamily, this kind contained the novel immune molecule called after of people " immunoglobulin-like receptor of originated from human dendritic cell " of two ITIM motifs, be abbreviated as HuDIgR (human dendritic cell derived Ig like receptor).
This albumen on nucleic acid and amino acid levels with ICR1, ICR2, CMRF35H apparent altitude homology.The HuDIgR assignment of genes gene mapping is distributed in the same area at karyomit(e) 17q25.2 with clusters such as ICR1, ICR2 and CMRF35H, so these genes may be to evolve through multiple gene replication from same ancestral gene.
Northern detect to show HuDIgR with the transcription of 1.8kb specifically high expression level do not reach and in its hetero-organization, see Table at peripheral blood mononuclear cell (PBMC) and spleen.RT-PCR analyzes and finds HuDIgR at PBMC, monocyte, and the DC of cells of monocytic origin, and the hematopoiesis of cells of monocytic origin is that cell (HL-60, NB4, THP-1 and U-937) has stronger expression.And other cells, the T cell of fresh separated and B cell, and other hematopoiesis is that cell (Jurkat, Molt4, Hut-78, Ramos, Raji, Daudi, K562 cell) does not all detect expression.NB4 and HL-60 cell are after the PMA activation, and the expression of HuDIgR obviously reduces, and THP-1 and U-937 cell are after the PMA activation, and the expression of HuDIgR finds no obvious variation; Jurkat, Molt4, Hut-78, Ramos, Raji, Daudi, K562 cell still do not detect the expression of HuDIgR after the PMA activation.
HuDIgR is expressed in monocyte, the tumour cell of cells of monocytic origin and dendritic cell surface, the specific expressed sign that this limitation expression pattern points out this albumen may become corresponding cell monoid differentiation, and the regulating effect of participation tumor growth and transfer.(monoclonalantibody MoAb) can be widely used in leukemic immunodiagnosis and magnetic target therapy to the monoclonal antibody of anti-HuDIgR.Siglec-3/CD33 has become the diagnosing acute marrow series leukemia, and (acute myelogenous leukemia, AML), especially the important symbol of undifferentiated type can be used for distinguishing AML and LL simultaneously.The anti-CD 33 monoclonal antibody has been applied to treat the clinical first phase research of AML, and alternative pernicious hematopoiesis, the answer normal hematopoiesis process removed.
HuDIgR and immunoglobulin superfamily member have higher homology, constitutional features with immunoglubulin superfaminly protein, can infer that HuDIgR passes through the ITIM motif conduction conditioning signal of its intracellular region, regulate and control multiple physiology and pathology activity, play a significant role, and may be worth having important development and application aspect the immunodiagnosis in a plurality of fields such as anti-infective, anti-inflammatory response, antitumor and nerve growth reparation, immunologic function adjusting and the immunotherapy.Research shows that immunoglubulin superfaminly protein is relevant with multiple vital movement.Therefore, significant for the human siali acid conjugated immunoglobulin-like agglutinant HuDIgR that diagnoses and the therapeutic purpose research and development is new.
In the present invention, term " HuDIgR albumen ", " HuDIgR polypeptide ", " immunoglobulin-like receptor of originated from human dendritic cell " or " immunoglobulin-like receptor HuDIgR " are used interchangeably, and all refer to have the albumen or the polypeptide of the immunoglobulin-like receptor HuDIgR aminoacid sequence (SEQ IDNO:2) of originated from human dendritic cell.
As used herein, " isolating " is meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.
As used herein, " isolating HuDIgR albumen or polypeptide " is meant that the HuDIgR polypeptide is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying HuDIgR albumen of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.
Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.
The present invention also comprises the proteic fragment of people HuDIgR, derivative and analogue.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep identical biological function of natural human HuDIgR albumen of the present invention or active polypeptide basically.Polypeptide fragment of the present invention, derivative or analogue can be that (i) has one or more conservative or substituted polypeptide of non-conservation amino-acid residue (preferred conservative amino acid residue), and the amino-acid residue of such replacement can be also can not encoded by genetic code, or (ii) in one or more amino-acid residues, has a polypeptide of substituted radical, or (iii) mature polypeptide and another compound (such as the compound that prolongs the polypeptide transformation period, polyoxyethylene glycol for example) merges formed polypeptide, or (iv) additional aminoacid sequence is fused to this peptide sequence and the polypeptide that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying, or with the fusion rotein of the segmental formation of antigen I gG).According to the instruction of this paper, these fragments, derivative and analogue belong to the known scope of those skilled in the art.
In the present invention, term " people HuDIgR polypeptide " refers to have the SEQ IDNO.2 polypeptide of sequence of people HuDIgR protein-active.This term also comprises having and variant form people HuDIgR albumen identical function, SEQ ID NO.2 sequence.These variant forms comprise (but being not limited to): several (are generally 1-50, preferably 1-30, more preferably 1-20,1-10 best) amino acid whose disappearance, insertion and/or replacement, and add one or several at C-terminal and/or N-terminal and (be generally in 20, preferably being in 10, more preferably is in 5) amino acid.For example, in the art, when replacing, can not change proteinic function usually with the close or similar amino acid of performance.Again such as, add one or several amino acid at C-terminal and/or N-terminal and also can not change proteinic function usually.This term also comprises proteic active fragments of people HuDIgR and reactive derivative.
The variant form of this polypeptide comprises: homologous sequence, conservative property varient, allelic variant, natural mutation, induced mutation body, under high or low tight degree condition can with the coded albumen of the DNA of people HuDIgR DNA hybridization and the polypeptide or the albumen that utilize the antiserum(antisera) of anti-people HuDIgR polypeptide to obtain.The present invention also provides other polypeptide, as comprises people HuDIgR polypeptide or its segmental fusion rotein.Except the polypeptide of total length almost, the present invention has also comprised the soluble fragments of people HuDIgR polypeptide.Usually, this fragment have people HuDIgR peptide sequence at least about 10 continuous amino acids, usually at least about 30 continuous amino acids, preferably at least about 50 continuous amino acids, more preferably at least about 80 continuous amino acids, best at least about 100 continuous amino acids.
Invention also provides the analogue of people HuDIgR albumen or polypeptide.The difference of these analogues and natural human HuDIgR polypeptide can be the difference on the aminoacid sequence, also can be the difference that does not influence on the modified forms of sequence, perhaps haves both at the same time.These polypeptide comprise natural or the inductive genetic variant.The induce variation body can obtain by various technology, as by radiation or be exposed to mutagenic compound and produce random mutagenesis, also can pass through site-directed mutagenesis method or the biological technology of other known moleculars.Analogue also comprises having the analogue that is different from the amino acid whose residue of natural L-(as D-amino acid), and has non-natural analogue that exist or synthetic amino acid (as β, gamma-amino acid).Should be understood that polypeptide of the present invention is not limited to the above-mentioned representational polypeptide that exemplifies.
(the not changing primary structure usually) form of modification comprises: the chemically derived form such as the acetylize or carboxylated of the polypeptide that body is interior or external.Modification also comprises glycosylation, carries out glycosylation modified and polypeptide that produce in the procedure of processing as those in the synthetic and processing of polypeptide or further.This modification can be carried out glycosylated enzyme (as mammiferous glycosylase or deglycosylating enzyme) and finishes by polypeptide is exposed to.Modified forms also comprises have the phosphorylated amino acid residue sequence of (as Tyrosine O-phosphate, phosphoserine, phosphothreonine).Thereby also comprise the polypeptide that has been improved its anti-proteolysis performance or optimized solubility property by modifying.
In the present invention, " people HuDIgR albumen conservative property variation polypeptide " refers to compare with the aminoacid sequence of SEQ ID NO:2, has 10 at the most, preferably at the most 8, more preferably at the most 5,3 amino acid is replaced by similar performance or close amino acid and is formed polypeptide at the most best.These conservative property variation polypeptide preferably carry out the amino acid replacement according to table 1 and produce.
Table 1
| Initial residue | Representational replacement | The preferred replacement |
| Ala(A) | Val；Leu；Ile | Val |
| Arg(R) | Lys；Gln；Asn | Lys |
| Asn(N) | Gln；His；Lys；Arg | Gln |
| Asp(D) | Glu | Glu |
| Cys(C) | Ser | Ser |
| Gln(Q) | Asn | Asn |
| Glu(E) | Asp | Asp |
| Gly(G) | Pro；Ala | Ala |
| His(H) | Asn；Gln；Lys；Arg | Arg |
| Ile(I) | Leu；Val；Met；Ala；Phe | Leu |
| Leu(L) | Ile；Val；Met；Ala；Phe | Ile |
| Lys(K) | Arg；Gln；Asn | Arg |
| Met(M) | Leu；Phe；Ile | Leu |
| Phe(F) | Leu；Val；Ile；Ala；Tyr | Leu |
| Pro(P) | Ala | Ala |
| Ser(S) | Thr | Thr |
| Thr(T) | Ser | Ser |
| Trp(W) | Tyr；Phe | Tyr |
| Tyr(Y) | Trp；Phe；Thr；Ser | Phe |
| Val(V) | Ile；Leu；Met；Phe；Ala | Leu |
Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:1 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that in the present invention coding has the protein of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:1.
The polynucleotide of the mature polypeptide of coding SEQ ID NO:2 comprise: the encoding sequence of an encoding mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.
Term " polynucleotide of coded polypeptide " can be the polynucleotide that comprise this polypeptide of encoding, and also can be the polynucleotide that also comprise additional code and/or non-coding sequence.
The invention still further relates to the varient of above-mentioned polynucleotide, its coding has the polypeptide of identical aminoacid sequence or fragment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.
The invention still further relates to and above-mentioned sequence hybridization and two sequences between have at least 50%, preferably at least 70%, the polynucleotide of at least 80% homogeny more preferably.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time is added with denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 90%, be more preferably 95% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ ID NO:2.
The invention still further relates to nucleic acid fragment with above-mentioned sequence hybridization.As used herein, the length of " nucleic acid fragment " contains 15 Nucleotide at least, better is at least 30 Nucleotide, is more preferably at least 50 Nucleotide, preferably more than at least 100 Nucleotide.Nucleic acid fragment can be used for the amplification technique (as PCR) of nucleic acid to determine and/or the proteic polynucleotide of separation coding HuDIgR.
Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.
People HuDIgR Nucleotide full length sequence of the present invention or its fragment can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention about nucleotide sequence, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.
In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.
In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually, by first synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.
At present, can be fully obtain the dna sequence dna of code book invention albumen (or its fragment, or derivatives thereof) by chemosynthesis.This dna sequence dna can be introduced in various existing dna moleculars as known in the art (or as carrier) and the cell then.In addition, also can will suddenly change and introduce in the protein sequence of the present invention by chemosynthesis.
Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to obtain the cDNA of total length from the library, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.
The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered with carrier of the present invention or HuDIgR albumen coded sequence, and the method that produces polypeptide of the present invention through recombinant technology.
Recombinant DNA technology (Science, 1984 by routine; 224:1431), can utilize polymerized nucleoside acid sequence of the present invention to can be used to express or produce the HuDIgR polypeptide of reorganization.In general following steps are arranged:
(1). with the polynucleotide (or varient) of coding of the present invention people HuDIgR polypeptide, or with the recombinant expression vector that contains these polynucleotide proper host cell that transforms or transduce;
(2). the host cell of in suitable medium, cultivating;
(3). separation, protein purification from substratum or cell.
Among the present invention, people HuDIgR polynucleotide sequence can be inserted in the recombinant expression vector.Term " recombinant expression vector " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carriers.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on T7 of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier can be used.A key character of expression vector is to contain replication orgin, promotor, marker gene and translation controlling elements usually.
Method well-known to those having ordinary skill in the art can be used to make up and contains people HuDIgR DNA sequences encoding and suitable transcribing/the translate expression vector of control signal.These methods comprise (Sambroook, et al.Molecular Cloning, a LaboratoryManual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; Lambda particles phage P
LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in protokaryon or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site and the transcription terminator that translation initiation is used.
In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance.
Comprise the carrier of above-mentioned suitable dna sequence dna and suitable promotor or control sequence, can be used to transform appropriate host cell, so that it can marking protein.
Host cell can be a prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; The bacterial cell of Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; The insect cell of fruit bat S2 or Sf9; The zooblast of CHO, COS, 293 cells or Bowes melanoma cells etc.
When polynucleotide of the present invention are expressed in higher eucaryotic cells, be enhanced if will make to transcribe when in carrier, inserting enhancer sequence.Enhanser is the cis acting factor of DNA, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.
Persons skilled in the art all know how to select appropriate carriers, promotor, enhanser and host cell.
Can carry out with routine techniques well known to those skilled in the art with the recombinant DNA transformed host cell.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results
2Method is handled, and used step is well-known in this area.Another kind method is to use MgCl
2If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, conventional mechanical method such as microinjection, electroporation, liposome packing etc.
The transformant that obtains can be cultivated with ordinary method, expresses the polypeptide of coded by said gene of the present invention.According to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.
The extracellular can be expressed or be secreted into to recombinant polypeptide in the above methods in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.The example of these methods includes, but are not limited to: conventional renaturation handles, with protein precipitant handle (salt analysis method), centrifugal, the broken bacterium of infiltration, superly handle, the combination of super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.
The people HuDIgR albumen or the polypeptide of reorganization are of use in many ways.These purposes include, but is not limited to: the direct disease due to the low or forfeiture and be used to screen and promote or antibody, polypeptide or other part of antagonism HuDIgR protein function as pharmacological agent HuDIgR protein function.The peptide molecule that can suppress or stimulate people HuDIgR protein function that can be used for seeking therapeutic value with the recombinant human HuDIgR protein screening peptide library of expressing.
On the other hand, the present invention also comprises people HuDIgR DNA or the polypeptide of its fragment coding has specific polyclonal antibody and monoclonal antibody, especially monoclonal antibody.Here, " specificity " is meant that antibody capable is incorporated into people HuDIgR gene product or fragment.Preferably, refer to that those can combine with people HuDIgR gene product or fragment but nonrecognition and be incorporated into the antibody of other irrelevant antigen molecule.Among the present invention antibody comprise those can in conjunction with and suppress the proteic molecule of people HuDIgR, comprise that also those do not influence the antibody of people HuDIgR protein function.The present invention also comprise those can with modify or without the people HuDIgR gene product bonded antibody of modified forms.
The present invention not only comprises complete mono-clonal or polyclonal antibody, but also comprises having immunocompetent antibody fragment, as Fab ' or (Fab)
2Fragment; Heavy chain of antibody; Light chain of antibody; Genetically engineered strand Fv molecule (people such as Ladner, U.S. Patent No. 4,946,778); Or chimeric antibody, as have the murine antibody binding specificity but still keep antibody from people's antibody moiety.
Antibody of the present invention can be prepared by the known various technology of those skilled in that art.For example, the people HuDIgR gene product of purifying or its have antigenic fragment, can be applied to animal to induce the generation of polyclonal antibody.Similarly, expressing human HuDIgR albumen or its have antigenic segmental cell and can be used to immune animal and produce antibody.Antibody of the present invention also can be monoclonal antibody.This type of monoclonal antibody can utilize hybridoma technology prepare (see people such as Kohler,
Nature256; 495,1975; People such as Kohler,
Eur.J.Immunol.6:511,1976; People such as Kohler,
Eur.J.Immunol.6:292,1976; People such as Hammerling,
In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., 1981).Antibody of the present invention comprises the antibody that can block people HuDIgR protein function and the antibody that does not influence people HuDIgR protein function.Each antibody-like of the present invention can utilize the fragment or the functional zone of people HuDIgR gene product, obtains by the routine immunization technology.These fragments or functional zone can utilize recombinant methods or utilize Peptide synthesizer synthetic.Can come immune animal and produce with the gene product of producing in the prokaryotic cell prokaryocyte (for example E.Coli) with the unmodified form bonded antibody of people HuDIgR gene product; With posttranslational modification form bonded antibody (as the albumen or the polypeptide of glycosylation or phosphorylation), can come immune animal and obtain with the gene product that produces in the eukaryotic cell (for example yeast or insect cell).
The proteic antibody of anti-people HuDIgR can be used in the immunohistochemistry technology, detects the people HuDIgR albumen in the biopsy specimen.In addition, with the also available labelled with radioisotope of the protein bound monoclonal antibody of people HuDIgR, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.
Antibody among the present invention can be used for treating or prevention and the relevant disease of people HuDIgR albumen.The antibody that gives suitable dosage can stimulate or block proteic generation of people HuDIgR or activity.
Antibody also can be used for being designed to the immunotoxin at a certain privileged sites in the body.As the monoclonal antibody of people HuDIgR albumen high-affinity can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing the cell (for example lymph-node cell etc.) of people HuDIgR protein positive.
The production of polyclonal antibody can choose HuDIgR albumen or polypeptide immune animal, as rabbit, mouse, rat etc.Multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.
Utilize albumen of the present invention,, can filter out with HuDIgR albumen interactional material takes place, as part, inhibitor, agonist or antagonist etc. by various conventional screening methods.
Albumen of the present invention and antibody thereof, inhibitor, agonist, antagonist or acceptor etc. when using (administration) in treatment, can provide different effects.Usually, can these materials are formulated in nontoxic, inert and the pharmaceutically acceptable aqueous carrier medium, wherein pH is about 5-8 usually, and preferably pH is about 6-8, although the pH value can be with being changed to some extent by preparation Substance Properties and illness to be treated.The pharmaceutical composition for preparing can carry out administration by conventional route, comprising (but being not limited to): intramuscular, intraperitoneal, intravenously, subcutaneous, intracutaneous or topical.
Polypeptide of the present invention can be directly used in disease treatment, for example, is used for tumour, inflammation, the treatment of neural system and cardiovascular diseases aspect.When using HuDIgR albumen of the present invention, also can use the other treatment agent simultaneously, as IFN-α, IFN-β, TNF-α, TNF-β etc.
The present invention also provides a kind of pharmaceutical composition, and it contains HuDIgR polypeptide of the present invention or its agonist, antagonist and the pharmaceutically acceptable carrier or the vehicle of safe and effective amount.This class carrier comprises (but being not limited to): salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.Pharmaceutical composition of the present invention can be made into the injection form, for example is prepared by ordinary method with the physiological saline or the aqueous solution that contains glucose and other assistant agents.Pharmaceutical composition such as tablet and capsule can be prepared by ordinary method.Pharmaceutical composition such as injection, solution, tablet and capsule should be made under aseptic condition.The dosage of activeconstituents is the treatment significant quantity, for example every day about 1 microgram/kg body weight-Yue 5 mg/kg body weight.In addition, polypeptide of the present invention also can use with the other treatment agent.
When making pharmaceutical composition, be that the HuDIgR albumen of safe and effective amount or its antagonist, agonist are applied to Mammals, wherein this safe and effective amount is usually at least about 10 micrograms/kg body weight, and in most of the cases be no more than about 8 mg/kg body weight, preferably this dosage is about 10 micrograms/kg body weight-Yue 1 mg/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.
The proteic polynucleotide of people HuDIgR also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the proteic expression of HuDIgR of the proteic nothing expression of HuDIgR or unusual/non-activity.The HuDIgR albumen that the gene therapy vector (as virus vector) of reorganization can be designed to express variation is to suppress endogenic HuDIgR protein-active.Deriving from viral expression vector such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for the HuDIgR transgenosis to cell.The method that structure carries the recombinant viral vector of HuDIgR gene is found in existing document (Sambrook, et al.).Recombinant human HuDIgR gene can be packaged in the liposome in addition, and then is transferred in the cell.
Suppress the oligonucleotide (comprising sense-rna and DNA) of people HuDIgRmRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.
Polynucleotide imports tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.
Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with the protein bound peptide molecule of people HuDIgR obtains.During screening, must carry out mark to people HuDIgR protein molecular.
The invention still further relates to the diagnostic testing process of quantitative and detection and localization people HuDIgR protein level.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The people HuDIgR protein level that is detected in the test can be with laying down a definition the importance of people HuDIgR albumen in various diseases and be used to the disease of diagnosing HuDIgR albumen to work.
Whether having the proteic method of HuDIgR in a kind of detection test sample is to utilize the proteic specific antibody of HuDIgR to detect, and it comprises: sample is contacted with the HuDIgR protein specific antibody; Observe whether form antibody complex, formed antibody complex and just represented to exist in the sample HuDIgR albumen.
The proteic polynucleotide of HuDIgR can be used for the diagnosis and the treatment of HuDIgR protein related diseases.Aspect diagnosis, the proteic polynucleotide of HuDIgR can be used for detecting the proteic expression of HuDIgR HuDIgR abnormal exprssion whether or under morbid state.Can be used for the hybridization of biopsy specimen to judge the proteic abnormal expression of HuDIgR as the HuDIgRDNA sequence.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out RNA-polymerase chain reaction (RT-PCR) amplification in vitro with the special primer of HuDIgR albumen and also can detect the proteic transcription product of HuDIgR.
The sudden change that detects the HuDIgR gene also can be used for the disease of diagnosing HuDIgR albumen relevant.The form of HuDIgR protein mutation comprises that the point mutation compared with normal wild type HuDIgR dna sequence dna, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.
Sequence of the present invention identifies it also is valuable to karyomit(e).In brief, the proteic cDNA of HuDIgR prepares PCR primer (preferred 15-35bp) according to the present invention, sequence can be positioned on the karyomit(e).Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.
In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, MendelianInheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.
In an example of the present invention, a kind of isolating polynucleotide are provided, its coding has the polypeptide of aminoacid sequence shown in the SEQ IDNO:2.Polynucleotide of the present invention are isolated from human dendritic cell cDNA library.Its sequence is shown in SEQ ID NO:1, and the polynucleotide sequence total length that it comprises is 1696 bases, and its open reading frame is positioned at the 7-876 position, and the coding total length is 290 amino acid whose people HuDIgR albumen (SEQ ID NO:2).This HuDIgR albumen contactin molecule, with ICR1, ICR2, CMRF35H apparent altitude homology, consistence can be up to more than 50% in Ig spline structure territory, and similarity then can reach 60%.RT-PCR analysis revealed HuDIgR has expression in some tumour cell, have expression in various degree simultaneously in peripheral blood lymphocytes and in the dendritic cell in different time LPS stimulated peripheral mononuclear cells source.The Northern engram analysis shows in peripheral blood, spleen to have particular expression.The research prompting of having carried out, HuDIgR may regulate and control multiple physiology and pathology activity by the ITIM motif conduction conditioning signal of its intracellular region, and the tool potential is antitumor, anti-inflammatory effect.Therefore, HuDIgR albumen or its relevant antagonist, agonist etc. can be diseases such as treatment tumour, inflammation, neural system and cardiovascular diseases new immunodiagnosis and targeted therapy approach are provided, thereby have great application prospect.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:ColdSpring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment 1: the clone of people HuDIgR cDNA
Extract the total RNA of human dendritic cell with Trizol reagent (Life Technologies).Then, from total RNA, separate poly (A) mRNA.Poly (A) mRNA after reverse transcription forms cDNA, is cloned test kit (Life Technologies) with SuperScriptII cDNA fragment orientation is inserted on the multiple clone site of carrier, transform DH5 α bacterium and form the cDNA plasmid library.Measure random choose clone's 5 ' terminal sequence with dideoxy method.CDNA sequence and the existing public dna sequence data storehouse measured are compared, found that a cDNA clone's dna sequence dna is new full-length cDNA.By synthetic a series of primers the contained dna sequence dna of new clone is carried out two-way mensuration.Computer Analysis shows that cloning contained full-length cDNA is a new cDNA sequence (shown in SEQ ID NO:1), the new protein (shown in SEQ ID NO:2) of encoding.This protein is named as the immunoglobulin-like receptor HuDIgR of originated from human dendritic cell, the immunoglobulin-like receptor HuDIgR gene of its encoding gene called after originated from human dendritic cell.
Sequence SEQ ID NO:1 total length is 1696bp, comprises 3 ' end non-coding region of 5 of 6bp ' end non-coding region and 817bp, and coding contains 290 amino acid whose polypeptide.Calculating not in theory, the molecular weight of glycosylated ripe molecule is about 31.2kD.Hydrophobicity analysis (Fig. 2) shows, the proteic N-end of HuDIgR is the extracellular fragment that 156 amino acid constitute, and comprises 23 amino acid whose signal peptides, and 156-178AA is that a hydrophobicity is striden the film district, the C-end is 112 amino acid whose born of the same parents' inner segments, and pointing out this molecule is an I type transmembrane protein.
They are different with known for the BLAST analysis revealed, with people ICR1, ICR2, CMRF35H apparent altitude homology in Ig spline structure territory inner amino acid array height homology, consistence reaches 50%, and similarity reaches 60% (Fig. 1), belongs to the recruit of immunoglobulin (Ig) family.
In addition, HuDIgR albumen structurally has the constitutional features of immunoglobulin superfamily, comprise and have a V-set Ig spline structure territory and three C2-set structural domains, contain conservative arginine and die aromatischen Aminosaeuren in the structural domain, specific conservative halfcystine pattern of rows and columns, and the ITIM motif of intracellular region etc.In addition, albumen also comprises 1 N-glycosylation site (88-91 residue), 1 CAMP_PHOSPHO_SITE (218-221), 3 PKC_PHOSPHO_SITE (81-83SIK, 216-218SPR, 221-223TTK), 8 CK2_PHOSPHO_SITE (44-47,69-72,71-74,81-84,94-97,101-104,113-116,131-134) and tyrosine phosphorylation site (276-284 residue).In HuDIgR albumen, comprise immunoglobulin (Ig) (Ig) and main histocompatibility and meet thing (major histocompatibility complex, MHC) albumen identifier, this prompting its contactin (IgSF) member.
Embodiment 2: carry out the cell expressing analysis of people HuDIgR with the RT-PCR method
Extract the total RNA of dendritic cell that is in the corresponding clone of logarithmic phase, human peripheral blood mononuclear cell and stimulates the human peripheral blood mononuclear cell of different time to originate through LPS with Trizol reagent, get 5 μ g cell total rnas and mix, carry out reverse transcription with 1 μ g Oligo-dT12-18.The reverse transcription system is 20 μ l, and reaction adds 80 μ l ddH after finishing
2O dilutes.The used primer of pcr amplification HuDIgR is as follows: adopted primer 5 ' ATCACCGGTCCAACAACAGT (SEQ ID NO:3) is arranged, antisense primer 5 ' GGGGAGGTGGCTACTGAG (SEQ ID NO:4), simultaneously with β-actin as positive control.The PCR reaction volume is 50 μ l, wherein contain reverse transcription template 10 μ l, 0.5mM primer, 0.2mM dNTP and 1U rTaqDNA polysaccharase (Takara Inc.), the amplification parameter be 95 ℃ 15 seconds, 57 ℃ 30 seconds, 72 ℃ 30 seconds, capable 1.5% agarose gel electrophoresis of PCR product is tentatively confirmed after 28 circulations.The dna sequence analysis result shows that the DNA sequences encoding of this PCR product and the 70-811 shown in the SEQ ID NO:1 are identical.
RT-PCR analyzes (Fig. 3) demonstration: HuDIgR at PBMC, monocyte, and the DC of cells of monocytic origin, and the hematopoiesis of cells of monocytic origin is that cell (HL-60, NB4, THP-1 and U-937) has stronger expression.And other cells, the T cell of fresh separated and B cell, and other hematopoiesis is that cell (Jurkat, Molt4, Hut-78, Ramos, Raji, Daudi, K562 cell) does not all detect expression.NB4 and HL-60 cell are after the PMA activation, and the expression of HuDIgR obviously reduces, and THP-1 and U-937 cell are after the PMA activation, and the expression of HuDIgR finds no obvious variation; Jurkat, Molt4, Hut-78, Ramos, Raji, Daudi, K562 cell still do not detect the expression of HuDIgR after the PMA activation.These results show that HuDIgR is a cell that is expressed in monocyte and cells of monocytic origin specifically.
Embodiment 3: the Northern engram analysis of people HuDIgR
Carry out the Northern trace by following ordinary method: filter membrane to be checked places the hybridization solution of 10ml through 68 ℃ of preheatings, in hybrid heater (Bellco) in 68 ℃ of prehybridizations 30 minutes; The cDNA probe that mark is good was in 95～100 ℃ of sex change 2～5 minutes, and (cDNA probe final concentration is 2～10ng/ml or 1～2 * 10 to put rapid cooling back adding hybridization solution on ice
6Cpm/ml), fully mixing was hybridized 2 hours in 68 ℃.After hybridization finishes, filter membrane with 2 * SSC, the drip washing of 0.05%SDS room temperature for several times, the washing lotion several is changed in continuing vibration flushing 30～40 minutes therebetween.Use 0.1 * SSC, 0.1%SDS in 50 ℃ of vibration flushings 20～40 minutes subsequently.Last filter membrane wrapped up with plastic fresh-keeping membrane, in-70 ℃ of exposure X line films 24～48 hours.
Northern blot hybridization result (Fig. 4) shows: have high abundance to express in peripheral blood, spleen (3.3kb), do not reach and see Table in other detection tissue, this shows that HuDIgR albumen is a kind of albumen of particular expression.
Embodiment 4 people HuDIgR are recombinant expressed
In this embodiment, be template with the total length plasmid DNA among the embodiment 1, increase with the PCR Oligonucleolide primers of 5 ' and 3 following ' end of sequence, obtain people HuDIgR DNA as inserting fragment.
5 ' end Oligonucleolide primers sequence of using in the PCR reaction is: 5 '-gtggatccttgaccgtgcagt-3 ' (SEQ ID NO:5)
This primer contains the restriction enzyme site of BamH1 restriction enzyme, is the part encoding sequence of people HuDIgR after this restriction enzyme site;
3 ' end primer sequence is: 5 '-cggaattctcaattccacaccag-3 ' (SEQ ID NO:6)
This primer contains the restriction enzyme site of EcoR I restriction enzyme and the part encoding sequence of people HuDIgR.
With the PCR product purification that obtains after EcoR I/BamH1 enzyme cut and recombinate according to a conventional method with plasmid pGEM-3ZF again and be converted into the competence e. coli bl21, the picking positive colony is identified back purifying and order-checking (377 type sequenators of ABI company, BigDye Terminator test kit, PE company).The people HuDIgR cDNA EcoR I/BamH1 endonuclease bamhi of correct sequence is cloned into expression vector pGEX-2T (Pharmacia), forms carrier pGEX-2T-HuDIgR, then transformed into escherichia coli BL21.Positive colony is cut evaluation with EcoR I/BamH I enzyme, the capable 0.8% agarose gel electrophoresis analysis of product.Confirm through order-checking, inserted designed HuDIgR encoding sequence.
Choosing the positive BL21 clone who expresses HuDIgR is inoculated in 100ml 2 * YTA substratum, 37 ℃ of 300rpm shaking culture 12-15hr, 2 * YTA the substratum that is diluted in preheating at 1: 10 continues shaking culture 1.5hr, add behind the 100mM IPTG to 0.1mM 30 ℃ and induce 2-6hr, 5,4 ℃ of centrifugal 10min of 000g remove supernatant, put and use 50ml 1 * PBS (0.14M NaCl on ice, 2.7mM KCl, 10.1mM Na
2HPO
4, 1.8mMKH
2PO
4PH7.3) resuspended, add 20%Triton X-100 to 1% jog 30min again after ultrasonic (B.Braun Labsonic U) fragmentation, then 12,4 ℃ of centrifugal 10min of 000g, supernatant with 0.8 μ m membrane filtration after, cross 1ml 50% glutathione S epharose 4B chromatography column, behind 1 * PBS thorough washing, (pH8.0) room temperature leaves standstill after 30 minutes and collects elutriant for 10mM gsh, 50mM Tris-HCl to add 500ul gsh elution buffer, repeat wash-out 2-3 time, obtain people HuDIgR-GST fusion rotein.The molecular weight of fusion rotein conforms to predictor.
Embodiment 5: anti-people HuDIgR production of antibodies
The recombinant protein people HuDIgR that obtains among the embodiment 4 is used for immune animal to produce antibody, and concrete grammar is as follows.Recombinant molecule is standby after separating with chromatography.Also available SDS-PAGE gel electrophoresis separates, electrophoretic band downcut from gel, and with isopyknic complete Freund ' s adjuvant emulsion.Albumen with 50-100 μ g/0.2ml emulsification carries out peritoneal injection to mouse.After 14 days,, mouse is carried out peritoneal injection with booster immunization with the dosage of 50-100 μ g/0.2ml with the same antigen of non-complete Freund ' s adjuvant emulsion.Carried out booster immunization one time every 14 days, carry out at least three times.The sero-fast specific reaction that obtains is active to be assessed in the ability of external precipitation people HuDIgR gene translation product with it.Found that antibody can combine with albumen of the present invention specifically.
Embodiment 6:HuDIgR raises tyrosine phosphatase SHP-1 by the tyrosine of its phosphorylation, SHP-2 and SHIP, mediation inhibitive ability of immunity signal
The plasmid DNA that will contain total length HuDIgR is with LipofectAMINE reagent (Life Technologies) transfection COS-7 cell, and 48 hours collecting cells after the transfection are handled cell (untreated cell is contrast) with the inhibitors of phosphatases sodium vanadate.The RIPA lysing cell, with anti-HIS antibody mediated immunity precipitation, immunoprecipitate is with anti-SHP-1, and SHP-2 and SHIP antibody carry out the Western trace and detect.
Test-results (Fig. 5) shows: HuDIgR can raise SHP-1 after phosphorylation, SHP-2, and SHIP, thereby mediation inhibitive ability of immunity signal.
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Sequence table
＜110〉Immunology Inst., No.2 Military Medical Univ.
＜120〉immunoglobulin-like receptor of novel originated from human dendritic cell, its encoding sequence and purposes
<130>024973
<160>6
<170>PatentIn version 3.1
<210>1
<211>1696
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(7)..(876)
<223>
<400>1
gagaag atg ccc ctg ctg aca ctc tac ctg ctc ctc ttc tgg ctc tca 48
Met Pro Leu Leu Thr Leu Tyr Leu Leu Leu Phe Trp Leu Ser
1 5 10
ggc tac tcc att gcc act caa atc acc ggt cca aca aca gtg aat ggc 96
Gly Tyr Ser Ile Ala Thr Gln Ile Thr Gly Pro Thr Thr Val Asn Gly
15 20 25 30
ttg gag cgg ggc tcc ttg acc gtg cag tgt gtt tac aga tca ggc tgg 144
Leu Glu Arg Gly Ser Leu Thr Val Gln Cys Val Tyr Arg Ser Gly Trp
35 40 45
gag acc tac ttg aag tgg tgg tgt cga gga gct att tgg cgt gac tgc 192
Glu Thr Tyr Leu Lys Trp Trp Cys Arg Gly Ala Ile Trp Arg Asp Cys
50 55 60
aag atc ctt gtt aaa acc agt ggg rca gag cag gag gtg aag agg gac 240
Lys Ile Leu Val Lys Thr Ser Gly Ser Glu Gln Glu Val Lys Arg Asp
65 70 75
cgg gtg tcc atc aag gac aat cag aaa aac cgc acg ttc act gtg acc 288
Arg Val Ser Ile Lys Asp Ash Gln Lys Ash Arg Thr Phe Thr Val Thr
80 85 90
atg gag gat ctc atg aaa act gat gct gac act tac tgg tgt gga att 336
Met Glu Asp Leu Met Lys Thr Asp Ala Asp Thr Tyr Trp Cys Gly Ile
95 100 105 110
gag aaa act gga aat gac ctt ggg gtc aca gtt caa gtg acc att gac 384
Glu Lys Thr Gly Asn Asp Leu Gly Val Thr Val Gln Val Thr Ile Asp
115 120 125
cca gca cca gtc acc caa gaa gaa act agc agc ttc cca act ctg acc 432
Pro Ala Pro Val Thr Gln Glu Glu Thr Ser Ser Phe Pro Thr Leu Thr
130 135 140
ggc cac cac ttg gac aac agg cac a8g ctc ctg aag ctc agt gtc ctc 480
Gly His His Leu Asp Asn Arg His Lys Leu Leu Lys Leu Ser Val Leu
145 150 155
ctg ccc ctc atc ttc acc ata ttg ctg ctg ctt ttg gtg gcc gcc tca 528
Leu Pro Leu Ile Phe Thr Ile Leu Leu Leu Leu Leu Val Ala Ala Ser
160 165 170
ctc ttg gct tgg agg atg atg aag tac cag cag aaa gca gcc ggg atg 576
Leu Leu Ala Trp Arg Met Met Lys Tyr Gln Gln Lys Ala Ala Gly Met
175 180 185 190
tcc cca gag cag gta ctg cag ccc ctg gag ggc gac ctc tgc tat gca 624
Ser Pro Glu Gln Val Leu Gln Pro Leu Glu Gly Asp Leu Cys Tyr Ala
195 200 205
gac ctg acc ctg cag ctg gcc gga acc tcc ccg cga aag gct acc acg 672
Asp Leu Thr Leu Gln Leu Ala Gly Thr Ser Pro Arg Lys Ala Thr Thr
210 215 220
aag ctt tcc tct gcc cag gtt gac cag gtg gaa gtg gaa tat gtc acc 720
Lys Leu Ser Ser Ala Gln Val Asp Gln Val Glu Val Glu Tyr Val Thr
225 230 235
atg gct tcc ttg ccg aag gag gac att tcc tat gca tct ctg acc ttg 768
Met Ala Ser Leu Pro Lys Glu Asp Ile Ser Tyr Ala Ser Leu Thr Leu
240 245 250
ggt gct gag gat cag gaa ccg acc tac tgc aac atg ggc cac ctc agt 816
Gly Ala Glu Asp Gln Glu Pro Thr Tyr Cys Asn Met Gly His Leu Ser
255 260 265 270
agc cac ctc ccc ggc agg ggc cct gag gag ccc acg gaa tac agc acc 864
Ser His Leu Pro Gly Arg Gly Pro Glu Glu Pro Thr Glu Tyr Ser Thr
275 280 285
atc agc agg cct tagcctgcac tccaggctcc ttcttggacc ccaggctgtg 916
Ile Ser Arg Pro
290
agcacactcc tgcctcatcg accgtctgcc ccctgctccc ctcatcagga ccaacccggg 976
gactggtgcc tctgcctgat cagccagcat tgcccctagc tctgggttgg gcttggggcc 1036
aagtctcagg gggcttctag gagttggggt tttctaaacg tcccctcctc tcctacatag 1096
ttgaggaggg ggctagggat atgctctggg gctttcatgg gaatgatgaa gatgataatg 1156
agaaaaatgt tatcattatt atcatgaagt accattatca taatacaatg aacctttatt 1216
tattgcctac cacatgttat gggctgaata atggccccca aagatatctg tgtcctaatc 1276
ctcagaactt gtgactgtta ccttctgtgg cagaaaggga cagtgcagat gtatgtaagt 1336
taaggacttt gagatagaga ggttattctt gctgattcag gtgggcccaa aatatcacca 1396
caagggtcct cataagaaag aggccagaag gtcaaagagg tagagacaaa gtgatgatgg 1456
aagtggacgt gggtgtgacg tgagcagggg ccatgaatgc cgcagccttc agatgccaga 1516
aagggaaagg aatggattcc cctgcctgga gcctccaaaa gaaaccagcc ctgcccacgc 1576
cttgacttga gcccattgaa actgatcttg agctcctggc ctccagaatt gcaggagaat 1636
aaatttgtgt tgtttttcat gagccaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1696
<210>2
<211>290
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>2
Met Pro Leu Leu Thr Leu Tyr Leu Leu Leu Phe Trp Leu Ser Gly Tyr
1 5 10 15
Ser I1e Ala Thr Gln Ile Thr Gly Pro Thr Thr Val Ash Gly Leu Glu
20 25 30
Arg Gly Ser Leu Thr Val Gln Cys Val Tyr Arg Ser Gly Trp Glu Thr
35 40 45
Tyr Leu Lys Trp Trp Cys Arg Gly Ala Ile Trp Arg Asp Cys Lys Ile
50 55 60
Leu Val Lys Thr Ser Gly Ser Glu Gln Glu Val Lys Arg Asp Arg Val
65 70 75 80
Ser Ile Lys Asp Asn Gln Lys Asn Arg Thr Phe Thr Val Thr Met Glu
85 90 95
Asp Leu Met Lys Thr Asp Ala Asp Thr Tyr Trp Cys Gly Ile Glu Lys
100 105 110
Thr Gly Asn Asp Leu Gly Val Thr Val Gln Val Thr Ile Asp Pro Ala
115 120 125
Pro Val Thr Gln Glu Glu Thr Ser Ser Phe Pro Thr Leu Thr Gly His
130 135 140
His Leu Asp Asn Arg His Lys Leu Leu Lys Leu Ser Val Leu Leu Pro
145 150 155 160
Leu Ile Phe Thr Ile Leu Leu Leu Leu Leu Val Ala Ala Ser Leu Leu
165 170 175
Ala Trp Arg Met Met Lys Tyr Gln Gln Lys Ala Ala Gly Met Ser Pro
180 185 190
Glu Gln Val Leu Gln Pro Leu Glu Gly Asp Leu Cys Tyr Ala Asp Leu
195 200 205
Thr Leu Gln Leu Ala Gly Thr Ser Pro Arg Lys Ala Thr Thr Lys Leu
210 215 220
Ser Ser Ala Gln Val Asp Gln Val Glu Val Glu Tyr Val Thr Met Ala
225 230 235 240
Ser Leu Pro Lys Glu Asp Ile Ser Tyr Ala Ser Leu Thr Leu Gly Ala
245 250 255
Glu Asp Gln Glu Pro Thr Tyr Cys Asn Met Gly His Leu Ser Ser His
260 265 270
Leu Pro Gly Arg Gly Pro Glu Glu Pro Thr Glu Tyr Ser Thr Ile Ser
275 280 285
Arg Pro
290
<210>3
<211>20
<212>DNA
＜213〉primer
<400>3
atcaccggtc caacaacagt 20
<210>4
<211>18
<212>DNA
＜213〉primer
<400>4
ggggaggtgg ctactgag 18
<210>5
<211>21
<212>DNA
＜213〉primer
<400>5
gtggatcctt gaccgtgcag t 21
<210>6
<211>23
<212>DNA
＜213〉primer
<400>6
cggaattctc aattccacac cag 23
Claims (10)
1. isolating people HuDIgR polypeptide is characterized in that this polypeptide is selected from down group:
(a) polypeptide of SEQ ID NO:2 aminoacid sequence;
(b) SEQ ID NO:2 aminoacid sequence is formed through replacement, disappearance or the interpolation of 1-10 amino-acid residue, and have raise tyrosine phosphatase SHP-1, SHP-2 or SHIP function by (a) polypeptides derived.
2. polypeptide as claimed in claim 1 is characterized in that, this polypeptide is the polypeptide of SEQ ID NO:2 aminoacid sequence.
3. isolating polynucleotide is characterized in that, this nucleotide sequence is selected from down group:
(a) polynucleotide of polypeptide as claimed in claim 1 or 2 of encoding;
(b) with the complete complementary polynucleotide of polynucleotide (a).
4. polynucleotide as claimed in claim 3 is characterized in that, the polypeptide of aminoacid sequence shown in this polynucleotide encoding SEQ ID NO:2.
5. polynucleotide as claimed in claim 3 is characterized in that, the sequence of these polynucleotide is selected from down a kind of of group:
(a) nucleotide sequence of 7-876 position among the SEQ ID NO:1;
(b) nucleotide sequence of 1-1696 position among the SEQ ID NO:1.
6. a carrier is characterized in that, it contains the described polynucleotide of claim 3.
7. a genetically engineered host cell is characterized in that, it contains the described carrier of claim 6.
8. method for preparing the described isolating people HuDIgR polypeptide of claim 1 is characterized in that this method comprises:
(a) under the condition that is fit to expressing human HuDIgR polypeptide, cultivate the described host cell of claim 7;
(b) from culture, isolate polypeptide with people HuDIgR polypeptide active.
9. energy and the described people HuDIgR of claim 1 polypeptid specificity bonded antibody.
10. a pharmaceutical composition is characterized in that, it contains the described polypeptide of claim 1 and the pharmaceutically acceptable carrier of safe and effective amount.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02136553.9A CN1273485C (en) | 2002-08-19 | 2002-08-19 | Immunoglobulin sample receptor originated from human dendritic cell, its coding sequence and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02136553.9A CN1273485C (en) | 2002-08-19 | 2002-08-19 | Immunoglobulin sample receptor originated from human dendritic cell, its coding sequence and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1477114A CN1477114A (en) | 2004-02-25 |
| CN1273485C true CN1273485C (en) | 2006-09-06 |
Family
ID=34146532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN02136553.9A Expired - Lifetime CN1273485C (en) | 2002-08-19 | 2002-08-19 | Immunoglobulin sample receptor originated from human dendritic cell, its coding sequence and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1273485C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104225627B (en) * | 2014-09-29 | 2016-09-14 | 武汉大学 | The leukocytic immunity globulin sample receptor subfamily B member 4 function and application in treatment atherosclerosis |
-
2002
- 2002-08-19 CN CN02136553.9A patent/CN1273485C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1477114A (en) | 2004-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1308346C (en) | Novel human phosphotidylethanolamine binding protein, its coding sequence and application | |
| CN1212334C (en) | Human siali acid conjugated immunoglobulin-like agglutinant, its coding sequence and use | |
| CN1273485C (en) | Immunoglobulin sample receptor originated from human dendritic cell, its coding sequence and application | |
| CN1300170C (en) | Novel DnaJ/Hsp40 molecule DC-DJIII, its coding sequence and application | |
| CN1163506C (en) | New human cell factor and its code sequence and use | |
| CN1290861C (en) | New type human bone marrow substrate cell source 1 type phosphoric acid enzyme inhibition factor, its coded sequence and use | |
| CN1223607C (en) | Human calcium ion/calmodulin dependent protein kinase II inhibitory protein and its application | |
| CN1277844C (en) | Novel human cyclin, its coding sequence and application | |
| CN1194012C (en) | Sperm formation relative protein and its coding sequence and use | |
| CN1234728C (en) | Novel human lymphokine, its coding sequence and use | |
| CN1289524C (en) | Human telomerase active inhibitor protein and use thereof | |
| CN1297999A (en) | Human glutaminyl s-RNA synthatase 58 as one new kind of polypeptide and polynucleotides encoding this polypeptide | |
| CN1151251C (en) | New human-phosphoguanosine reductase, its coding sequence and application | |
| CN1152957C (en) | Human 6-phosphoglucosamine isomerase, its code sequence and application | |
| CN1171901C (en) | New interferon-like protein and its code sequence and use | |
| CN1408724A (en) | Novel testicular function relative protein and its use | |
| CN1304568C (en) | Novel human complement C1r-like serine proteinase analogue, and its encoding sequence and use | |
| CN1534043A (en) | Ubiquition type molecule of human bone marrow substrate cell source and its coding sequence and use | |
| CN1566149A (en) | Immunosuppressive receptor derived from dendritic cell, coded sequence and uses thereof | |
| CN1631898A (en) | Mitochondria traffic protein molecule for human marrow stromal cell and sequence encoding same and use thereof | |
| CN1148381C (en) | New human chemotaxis factor macrophage inflammatory protein, its coding sequence and use | |
| CN1603341A (en) | Human calcium ion / calmodulin deopendent protein kinase II inhibitory protein alpha, its coded sequence and use | |
| CN1169832C (en) | Identification and function research of gene p28-II | |
| CN1718729A (en) | Function and use of human immune cell inhibition acceptor KLRL1 | |
| CN1208344C (en) | Novel human cell endocytic regulatory protein, its coding sequence and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060906 |